17.01.2022 13:00:00

This Could Be Another Blockbuster Indication for AstraZeneca

Recently, AstraZeneca (NASDAQ: AZN) announced what could be very positive regulatory news for one of its rare disease drugs. The pharma stock informed shareholders that the U.S. Food and Drug Administration (FDA) accepted the regulatory submission under priority review for Ultomiris to treat adults diagnosed with the rare condition called generalized myasthenia gravis (gMG). With the FDA targeting a decision on the drug during the second quarter of this year, let's dig into the efficacy of Ultomiris and its sales potential. Image source: Getty Images.Continue reading
Read more on "MotleyFool"

Analysen zu :be AG Inhaber-Aktmehr Analysen

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!

Aktien in diesem Artikel

:be AG Inhaber-Akt 4,90 0,00% :be AG Inhaber-Akt
AstraZeneca PLC ADR Cert. Deposito Arg. Repr. 2 ADRs 6 949,00 1,36% AstraZeneca PLC ADR Cert. Deposito Arg. Repr. 2 ADRs
AstraZeneca PLC 125,00 2,88% AstraZeneca PLC
AstraZeneca PLC (spons. ADRs) 61,40 1,32% AstraZeneca PLC (spons. ADRs)